Form 4: Moderna CFO's Routine Stock Transactions Reported

Moderna's Chief Financial Officer, James M. Mock, reported the vesting of restricted stock units and subsequent sale of shares for tax obligations.

Summary

• James M. Mock, Moderna's Chief Financial Officer, reported transactions involving company stock.
• On December 5, 2025, 47,190 restricted stock units (RSUs) vested and converted into common stock on a one-for-one basis.
• Concurrently, 22,817 shares of common stock were disposed of at a price of $25.49 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Mock beneficially owns 43,200 shares of common stock directly and 141,571 derivative securities (RSUs).
• The RSU award vests 25% on December 5, 2025, with the remaining portion vesting in twelve equal quarterly installments thereafter.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations. This is a standard event and does not indicate a significant change in company outlook or performance, leaning slightly positive due to compensation vesting.

Positives

• Vesting of 47,190 restricted stock units, representing a component of executive compensation for the Chief Financial Officer.
• Continued beneficial ownership of 141,571 derivative securities (RSUs) and 43,200 common shares, aligning management's interests with shareholders.

Negatives

• Disposition of 22,817 shares of common stock, although this was for tax withholding purposes and not a discretionary sale.

Future Outlook

The remaining 75% of the restricted stock unit award will vest in twelve equal quarterly installments following December 5, 2025.

Industry Context

NA

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event for an executive, not a discretionary sale indicating a change in sentiment.
• Employees: Reflects standard executive compensation practices, which may be viewed as a positive for executive retention and motivation.

Next Steps

• The remaining 75% of the restricted stock unit award will vest in twelve equal quarterly installments following December 5, 2025.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Transaction, CFO, Restricted Stock Units, Stock Vesting, Executive Compensation